Prelude Therapeutics PRT3789 Phase 1 interim data: 4 PRs; DAC program preclinical proof-of-concept

Prelude Therapeutics Inc

Interim Phase 1 results: 4 confirmed partial responses (2 esophageal, 2 NSCLC) out of 26 evaluable SMARCA4 loss-of-function patients.
PRT3789 generally well-tolerated; no dose-limiting toxicities or drug-related SAEs; higher doses (≥212 mg) show deeper SMARCA2 degradation.
Combination with docetaxel shows acceptable safety profile; preclinical data show synergy with chemo in SMARCA4-mutant NSCLC models.
First preclinical proof-of-concept for SMARCA2/4 dual degrader antibody conjugates (DACs): anti-PSMA DACs show efficacy and tolerability in xenograft models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.